DFDA

Clinical Trials for Psoriasis

Focusing on: Secukinumab

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Specify a medical condition you are interested in.

Specify a drug, device, or procedure if you are looking for trials for a specific intervention.

Displaying 10 of 146 results.

Page 1 of 15
Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)
Completed
Conditions:Psoriasis
Interventions:Secukinumab
Study Type: OBSERVATIONAL
Phase: N/A
Enrollment: 17743
Age: 18 Years - 100 Years
Gender: ALL
Locations: Novartis Investigative Site
View Study Details
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
Completed
Conditions:Psoriasis
Interventions:secukinumab
Study Type: OBSERVATIONAL
Phase: N/A
Enrollment: 1002
Age: 18 Years - 100 Years
Gender: ALL
Locations: Novartis Investigative Site; Novartis Investigative Site; +40 more
View Study Details
Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects
Completed
Conditions:Psoriasis
Study Type: INTERVENTIONAL
Phase: PHASE1
Enrollment: 216
Age: 18 Years - 55 Years
Gender: MALE
Locations: The First Hospital of Jilin University
View Study Details
Immunologic Response to Secukinumab in Plaque Psoriasis
Completed
Conditions:Psoriasis
Interventions:Secukinumab
Study Type: INTERVENTIONAL
Phase: PHASE4
Enrollment: 15
Age: From 18 Years
Gender: ALL
Locations: UCSF Psoriasis and Skin Treatment Center
Has Results
View Study Details
Secukinumab Efficacy Without the Initial Loading Dose in Patients With Psoriasis
Completed
Study Type: OBSERVATIONAL
Phase: N/A
Enrollment: 156
Age: From 18 Years
Gender: ALL
Locations: University of Verona
View Study Details
Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis
Completed
Conditions:Psoriasis
Interventions:Secukinumab
Study Type: OBSERVATIONAL
Phase: N/A
Enrollment: 1518
Age: 18 Years - 100 Years
Gender: ALL
Locations: Novartis Pharmaceuticals
View Study Details
An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source
Completed
Conditions:Plaque Psoriasis
Interventions:Secukinumab
Study Type: OBSERVATIONAL
Phase: N/A
Enrollment: 767
Age: 18 Years - 99 Years
Gender: ALL
Locations: Novartis Investigative Site
View Study Details
Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab
Completed
Conditions:Psoriasis
Study Type: INTERVENTIONAL
Phase: PHASE3
Enrollment: 151
Age: From 18 Years
Gender: ALL
Locations: Novartis Investigative Site; Novartis Investigative Site; +21 more
Has Results
View Study Details
Safety and Efficacy of Secukinumab in Mild Psoriasis
Completed
Conditions:Psoriasis
Study Type: INTERVENTIONAL
Phase: PHASE2
Enrollment: 23
Age: From 18 Years
Gender: ALL
Locations: The Rockefeller Univesity
Has Results
View Study Details
A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis
Completed
Conditions:Psoriasis
Interventions:Secukinumab
Study Type: INTERVENTIONAL
Phase: PHASE4
Enrollment: 20
Age: From 18 Years
Gender: ALL
Locations: Mount Sinai West Dermatolgy
View Study Details